Stocks and Investing Stocks and Investing
Wed, May 15, 2024

Etzer Darout Reiterated (ACRV) at Buy and Held Target at $25 on, May 15th, 2024


Published on 2024-10-28 11:23:13 - WOPRAI, Etzer Darout
  Print publication without navigation


Etzer Darout of BMO Capital, Reiterated "Acrivon Therapeutics, Inc." (ACRV) at Buy and Held Target at $25 on, May 15th, 2024.

Etzer has made no other calls on ACRV in the last 4 months.



There are 4 other peers that have a rating on ACRV. Out of the 4 peers that are also analyzing ACRV, 1 agrees with Etzer's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Aydin Huseynov of "Ladenburg Thalmann" Downgraded from Strong Buy to Hold on, Monday, April 29th, 2024


These are the ratings of the 3 analyists that currently disagree with Etzer


  • Emily Bodnar of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $22 on, Tuesday, May 14th, 2024
  • Joseph Catanzaro of "Piper Sandler" Maintained at Buy with Increased Target to $30 on, Thursday, April 25th, 2024
  • Silvan Tuerkcan of "JMP Securities" Maintained at Buy with Increased Target to $17 on, Thursday, April 25th, 2024
Contributing Sources